Get the Daily Brief
Latest Biotech News
USP issues GLP‑1 quality resources as counterfeit risk and demand surge
The U.S. Pharmacopeia released reference standards and analytical reference materials to help manufacturers ensure purity and detect impurities in GLP‑1 peptide products amid unprecedented demand...
Hemab raises $157M to tackle underserved coagulation disorders
Hemab Therapeutics closed a $157 million financing to advance a portfolio targeting rare bleeding disorders including Glanzmann thrombasthenia and von Willebrand disease. The round was led by...
Novartis doubles down on RNA: $12B Avidity buy
Novartis agreed to acquire Avidity Biosciences in a roughly $12 billion cash deal that brings three late‑stage antibody‑oligonucleotide conjugate (AOC) programs into its neuroscience portfolio....
Intellia halts nex‑z trials after liver toxicity
Intellia Therapeutics paused enrollment and dosing in two Phase III trials of its in vivo CRISPR candidate (nex‑z) after a study participant was hospitalized with severe liver injury. The company...
BridgeBio’s phase 3 win: FDA meeting looms
BridgeBio reported a positive interim Phase III readout for BBP‑418 in limb‑girdle muscular dystrophy 2I/R9, meeting pre‑specified efficacy thresholds and prompting plans to meet the FDA to...
Zenas posts near‑complete lesion suppression in MS phase 2
Zenas Biopharma announced mid‑stage MoonStone data showing its bifunctional monoclonal antibody obexelimab produced a 95% reduction in new gadolinium‑enhancing brain lesions in relapsing multiple...
Hemab secures $157M to target underserved coagulation disorders
Hemab Therapeutics closed a $157 million financing to advance a portfolio focused on rare and underserved coagulation disorders, including lead programs moving toward pivotal testing. The funds...
MARTi brings real‑time metagenomics to nanopore sequencing
Researchers at the Earlham Institute released MARTi, an open‑source software suite enabling real‑time analysis and visualization of nanopore metagenomic data. MARTi combines a lightweight analysis...
BoltzGen expands AI drug design: From structure to therapeutics
An MIT‑led team unveiled BoltzGen, a supercomputer‑trained AI model that moves beyond high‑accuracy structure prediction to generalizable therapeutic design across modalities — nanobodies,...
Guardant and Zephyr tie up: AI meets circulating tumor genomics
Guardant Health entered a strategic partnership with Zephyr AI to combine Guardant’s multimodal molecular data from its genomic testing platform with Zephyr’s analytics to accelerate biomarker...
USP releases GLP‑1 standards: Quality push amid fraud and shortages
The U.S. Pharmacopeia released reference standards and analytical reference materials (ARMs) to help manufacturers test GLP‑1 peptide therapeutics for product‑ and process‑related impurities. USP...
NHS vets 15‑minute blood test for sepsis screening in children
Three pediatric emergency departments in England are trialing Memed BV’s rapid blood test, which produces results in as little as 15 minutes to differentiate bacterial from viral infections. The...
Novartis buys Avidity for $12B — secures three late‑stage RNA neuromuscular drugs
Novartis agreed to acquire Avidity Biosciences for roughly $12 billion, adding three antibody‑oligonucleotide conjugate (AOC) programs aimed at Duchenne muscular dystrophy (DMD), myotonic...
Intellia halts Phase 3 CRISPR dosing — liver safety probe underway
Intellia Therapeutics paused enrollment and dosing in two late‑stage trials of its CRISPR therapy nex‑z after a trial volunteer was hospitalized with severe liver injury. The company stopped...
Zenas’ obexelimab nearly eradicates new MS lesions — mid‑stage readout
Zenas Biopharma reported a mid‑stage (MoonStone) trial in relapsing multiple sclerosis where obexelimab, a bifunctional monoclonal antibody, produced a roughly 95% reduction in new...
BridgeBio posts positive Phase 3—prepares FDA meeting for rare muscular dystrophy filing
BridgeBio announced a positive interim Phase 3 readout for BBP‑418 (ribitol) in limb‑girdle muscular dystrophy type 2I/R9, meeting prespecified thresholds and producing clinically meaningful...
Hemab raises $157M to build 'ultimate coagulation disorders' company
Hemab Therapeutics closed a $157 million financing to advance a portfolio of coagulation‑disorder programs, including a sutacimig pivotal trial planned for Glanzmann thrombasthenia and an...
Real‑time nanopore metagenomics: MARTi enables in‑field pathogen surveillance
Researchers at the Earlham Institute released MARTi, an open‑source software suite that enables real‑time analysis and visualization of nanopore metagenomic data. MARTi runs on standard laptops or...
USP issues GLP‑1 quality standards as nonresponse and counterfeits spotlight market risks
The U.S. Pharmacopeia released reference standards and analytical reference materials to help manufacturers test GLP‑1 peptide therapeutics for product‑ and process‑related impurities amid surging...
New Streptomyces intermediate yields potent antibiotic lead against MRSA and VRE
Researchers identified a previously untested biosynthetic intermediate—pre‑methylenomycin C lactone—from Streptomyces coelicolor that shows markedly higher activity against Gram‑positive pathogens...